On October 20th, Baekje announced that the National Institute of Health and Clinical Optimization (NICE) in the UK has released a final evaluation document recommending the company's product, Baekje&Co; Reg; Zebutinib capsules are used to treat adult patients who meet the following criteria for indication treatment: untreated chronic lymphoblastic leukemia (CLL) with 17p deficiency or TP53 mutation (high-risk) or untreated CLL without 17p deficiency or TP53 mutation, and are not suitable for receiving fludarabine cyclophosphamide rituximab (FCR) or bendamustine combined with rituximab (BR) treatment; And recurrent/refractory CLL.
Baiyue Ze& Reg; Zebutinib Capsules is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) independently developed by the company. It is currently undergoing extensive clinical trials worldwide as a single drug and in combination with other therapies for the treatment of various B-cell malignancies. Due to the continuous synthesis of new BTK in the human body, Baiyue Ze& Reg; The design achieves complete and sustained inhibition of BTK protein by optimizing bioavailability, half-life, and selectivity.